Share ownership Indivior PLC London S.E.

INDV

GB00BN4HT335

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:04 2025-07-24 EDT			5-day change	1st Jan Change
1,238.00 ^GBX	+1.56%		-.--%	+20.90%

11-14	Camurus Competitor Exits Sweden - Di	FW
11-03	Indivior Presents New Real-World Evidence At AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine	CI

Share class: Indivior PLC

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	124,137,286	119,305,018 ( 96.11 %)	0	96.11 %

Major shareholders: Indivior PLC

Name	Equities	%	Valuation
Two Seas Capital LP 8.419 %	10,504,152	8.419 %	309 M p
Two Seas Capital LP 7.417 %	9,254,152	7.417 %	272 M p
Oaktree Capital Management LP 7.009 %	8,745,084	7.009 %	257 M p
BlackRock Advisors LLC 6.512 %	8,124,988	6.512 %	239 M p
Madison Avenue Partners LP 5.962 %	7,438,153	5.962 %	218 M p
Deerfield Management Co. LP 5.6 %	6,986,811	5.6 %	205 M p
Deerfield Management Co. LP (Private Equity) 5.6 %	6,986,811	5.6 %	205 M p
Société Générale Gestion SA 5.423 %	6,766,479	5.423 %	199 M p
Goldman Sachs Asset Management LP 5.271 %	6,576,848	5.271 %	193 M p
Goldman Sachs & Co. LLC (Private Banking) 5.235 %	6,531,868	5.235 %	192 M p
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	126.17%
Other	11.41%
Individuals	3.51%
State Street Corp.	2.26%
Schweizerische Nationalbank	0.16%
SEI Investments Co.	0.15%
Manulife Financial Corp.	0.04%
Rathbones Group Plc	0.03%
Sumitomo Mitsui Trust Group, Inc.	0.02%
Governments	0.02%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	121.01%
United Kingdom	10.9%
France	5.42%
Individuals	3.51%
Switzerland	0.99%
Canada	0.71%
Australia	0.42%
Ireland	0.34%
Cayman Islands	0.16%
Hong Kong	0.09%
Germany	0.07%
Japan	0.06%
Norway	0.04%
Brazil	0.02%
China	0.02%
South Korea	0.01%

Based on 1000 largest holdings

Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.

Employees

1,041

Sector

Pharmaceuticals

Calendar

02-11 - Q4 2025 Earnings Release (Projected)

More about the company